Annovis Bio, Inc. (NYSE:ANVS – Get Free Report) saw a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 1,360,000 shares, a growth of 12.4% from the September 30th total of 1,210,000 shares. Based on an average daily trading volume, of 248,000 shares, the days-to-cover ratio is presently 5.5 days.
Annovis Bio Stock Down 2.6 %
Annovis Bio stock traded down $0.25 during mid-day trading on Thursday, reaching $9.30. 242,467 shares of the company’s stock traded hands, compared to its average volume of 792,053. The company has a market cap of $121.40 million, a price-to-earnings ratio of -1.82 and a beta of 1.72. The stock has a 50 day moving average of $8.59 and a two-hundred day moving average of $8.52. Annovis Bio has a 12-month low of $4.53 and a 12-month high of $22.49.
Annovis Bio (NYSE:ANVS – Get Free Report) last released its quarterly earnings results on Thursday, August 15th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.19. As a group, sell-side analysts forecast that Annovis Bio will post -2.53 earnings per share for the current year.
Institutional Investors Weigh In On Annovis Bio
Wall Street Analysts Forecast Growth
A number of equities analysts have weighed in on ANVS shares. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Annovis Bio in a research report on Wednesday, October 16th. EF Hutton Acquisition Co. I upgraded shares of Annovis Bio to a “strong-buy” rating in a research report on Tuesday, August 13th. Finally, Maxim Group upgraded shares of Annovis Bio from a “hold” rating to a “buy” rating and set a $25.00 price target for the company in a research report on Friday, October 25th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $32.17.
View Our Latest Stock Analysis on Annovis Bio
Annovis Bio Company Profile
Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.
Read More
- Five stocks we like better than Annovis Bio
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- Ride Out The Recession With These Dividend Kings
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.